Literature DB >> 19001952

The direct and indirect cost burden of Crohn's disease and ulcerative colitis.

Teresa B Gibson1, Eliza Ng, Ronald J Ozminkowski, Shaohung Wang, Wayne N Burton, Ron Z Goetzel, Ross Maclean.   

Abstract

OBJECTIVE: To estimate the direct medical and indirect (absenteeism and short-term disability) cost burden of Crohn's Disease (CD) and Ulcerative Colitis (UC).
METHODS: Data were obtained from 1999 to 2005 MarketScan databases. Twelve-month expenditures for patients with CD and UC were compared to expenditures among an equal number of propensity score matched comparison group patients. Regression analysis controlled for demographics and case-mix.
RESULTS: Annual medical expenditures were significantly higher for commercially insured CD and UC patients compared to matched comparison group patients ($18,963 vs $5300 for CD patients, $15,020 vs $4982 for UC patients, respectively, all P < 0.001). Indirect costs were also high for employed patients with these conditions.
CONCLUSIONS: CD and UC are costly diseases with a significant cost burden related to health care utilization and productivity loss.

Entities:  

Mesh:

Year:  2008        PMID: 19001952     DOI: 10.1097/JOM.0b013e318181b8ca

Source DB:  PubMed          Journal:  J Occup Environ Med        ISSN: 1076-2752            Impact factor:   2.162


  51 in total

1.  Cost utility of inflammation-targeted therapy for patients with ulcerative colitis.

Authors:  Sameer D Saini; Akbar K Waljee; Peter D R Higgins
Journal:  Clin Gastroenterol Hepatol       Date:  2012-05-18       Impact factor: 11.382

2.  Assessing National Trends and Disparities in Ambulatory, Emergency Department, and Inpatient Visits for Inflammatory Bowel Disease in the United States (2005-2016).

Authors:  Christopher Ma; Matthew K Smith; Leonardo Guizzetti; Remo Panaccione; Gilaad G Kaplan; Kerri L Novak; Cathy Lu; Reena Khanna; Brian G Feagan; Siddharth Singh; Vipul Jairath; Ashwin N Ananthakrishnan
Journal:  Clin Gastroenterol Hepatol       Date:  2020-01-25       Impact factor: 11.382

3.  Optimizing management of Crohn's disease within a project management framework: results of a pilot study.

Authors:  Laurie Keefer; Bethany Doerfler; Caroline Artz
Journal:  Inflamm Bowel Dis       Date:  2011-02-23       Impact factor: 5.325

4.  The potential role of a self-management intervention for ulcerative colitis: a brief report from the ulcerative colitis hypnotherapy trial.

Authors:  Laurie Keefer; Jennifer L Kiebles; Monika A Kwiatek; Olafur Palsson; Tiffany H Taft; Zoran Martinovich; Terrence A Barrett
Journal:  Biol Res Nurs       Date:  2011-02-28       Impact factor: 2.522

5.  Age Modifies the Association Between Depressive Symptoms and Adherence to Self-Testing With Telemedicine in Patients With Inflammatory Bowel Disease.

Authors:  Kenechukwu Chudy-Onwugaje; Ameer Abutaleb; Andrea Buchwald; Patricia Langenberg; Miguel Regueiro; David A Schwartz; J Kathleen Tracy; Leyla Ghazi; Seema A Patil; Sandra Quezada; Katharine Russman; Sara Horst; Dawn Beaulieu; Charlene Quinn; Guruprasad Jambaulikar; Raymond K Cross
Journal:  Inflamm Bowel Dis       Date:  2018-11-29       Impact factor: 5.325

Review 6.  The economic and quality-of-life burden of Crohn's disease in Europe and the United States, 2000 to 2013: a systematic review.

Authors:  David N Floyd; Sue Langham; Hélène Chevrou Séverac; Barrett G Levesque
Journal:  Dig Dis Sci       Date:  2014-09-26       Impact factor: 3.199

Review 7.  Impact of inflammatory bowel disease on disability.

Authors:  Katharina Büsch; Amnon Sonnenberg; Nick Bansback
Journal:  Curr Gastroenterol Rep       Date:  2014-10

8.  Demographic and Clinical Predictors of High Healthcare Use in Patients with Inflammatory Bowel Disease.

Authors:  Benjamin Click; Claudia Ramos Rivers; Ioannis E Koutroubakis; Dmitriy Babichenko; Alyce M Anderson; Jana G Hashash; Michael A Dunn; Marc Schwartz; Jason Swoger; Leonard Baidoo; Arthur Barrie; Miguel Regueiro; David G Binion
Journal:  Inflamm Bowel Dis       Date:  2016-06       Impact factor: 5.325

9.  Long-term direct costs before and after proctocolectomy for ulcerative colitis: a population-based study in Olmsted County, Minnesota.

Authors:  Stefan D Holubar; Kirsten Hall Long; Edward V Loftus; Bruce G Wolff; John H Pemberton; Robert R Cima
Journal:  Dis Colon Rectum       Date:  2009-11       Impact factor: 4.585

Review 10.  Therapy with stem cells in inflammatory bowel disease.

Authors:  María Del Pilar Martínez-Montiel; Gonzalo Jesús Gómez-Gómez; Ana Isabel Flores
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.